Lonza O6Z

SGD 79.97 +0.00% +0.00 Updated 17 Nov 2026, 15:48 SGT

Company profile

The business, the people and the ownership behind Lonza.

Business overview

About the company

Lonza provides services and technologies through its Integrated Biologics, Advanced Synthesis and Specialized Modalities businesses. These are its reported continuing operating segments.

Annual Report 2025 ↗ Reviewed 2026-10-23 · Source dated 2026-04-01. PDF p. 38

Listed security

Company & listing

Full Company Name
LONZA GROUP LTD
Trading Currency
SGD
Website
www.lonza.com
Listing
Listed on 21 October 2011 on SGX Mainboard
ISIN Code
CH0013841017

Board & management

Leadership

Jean-Marc Huët

Independent

Board of Directors as of 31 December 2025 As reported at 2025-12-31

Jürgen Steinemann

Independent

Board of Directors as of 31 December 2025 As reported at 2025-12-31

Christoph Mäder

Independent

Board of Directors as of 31 December 2025 As reported at 2025-12-31

Juan Andres

Independent

Board of Directors as of 31 December 2025 As reported at 2025-12-31

Eric Drapé

Independent

Board of Directors as of 31 December 2025 As reported at 2025-12-31

Marion Helmes

Independent

Board of Directors as of 31 December 2025 As reported at 2025-12-31

Angelica Kohlmann

Independent

Board of Directors as of 31 December 2025 As reported at 2025-12-31

David Meline

Independent

Board of Directors as of 31 December 2025 As reported at 2025-12-31

Roger Nitsch

Independent

Board of Directors as of 31 December 2025 As reported at 2025-12-31

Barbara Richmond

Independent

Board of Directors as of 31 December 2025 As reported at 2025-12-31

Wolfgang Wienand

Chief Executive Officer

Executive Committee as of 31 December 2025 As reported at 2025-12-31

Roles listed in Annual Report 2025; current appointments are not independently verified.

Holdings

Ownership

BlackRock, Inc.

New York, NY (USA); held 9.85% of Lonza's share capital

Principal Shareholders; more than 3% of share capital per disclosure notifications

UBS Fund Management (Switzerland) AG

Basel, Switzerland; held 6.246% of Lonza's share capital

Principal Shareholders; more than 3% of share capital per disclosure notifications

Total interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.

Group structure

Main operating subsidiaries

CompanyMarketOwnership interest
BioAtrium AGHolding Indirect Visp CH; holding indirect 50%
Capsugel Australia Pty LtdHolding Indirect Sydney AUS; holding indirect 100%
Capsugel Belgium NVHolding Indirect Bornem BE; holding indirect 100%
Capsugel Canada Corp.Holding Indirect Vancouver CA; holding indirect 100%
Capsugel Italy SrlHolding Indirect Milan IT; holding indirect 100%
Capsugel de México, S. de R.L. de C.V.Holding Indirect Puebla ME; holding indirect 100%
Capsugel Distribucion, S. de R.L. de C.V.Holding Indirect Puebla ME; holding indirect 100%
Capsugel France SASHolding Indirect Colmar FR; holding indirect 100%
Capsugel Healthcare Private LimitedHolding Indirect Gurugram IN; holding indirect 99.9%
Komec N.V.Holding Indirect Wilrijk BE; holding indirect 100%
LLC CapsugelHolding Indirect Kuzminki (city of Moscow) RU; holding indirect 100%
Lonza AGHolding Indirect Visp CH; holding indirect 100%
Lonza Bend lnc.Holding Indirect Portland US; holding indirect 100%
Lonza Biologics IncHolding Indirect Wilmington US; holding indirect 100%
Lonza Biologics Ltd.Holding Indirect Guangzhou CN; holding indirect 100%
Lonza Biologics plcHolding Indirect Slough GB; holding indirect 100%
Lonza Biologics Porriño S.L.Holding Indirect Porriño ES; holding indirect 100%
Lonza Biologics Tuas Pte. Ltd.Holding Indirect Singapore SG; holding indirect 100%
Lonza Bioscience Singapore Pte LtdHolding Indirect Singapore SG; holding indirect 100%
Lonza Cologne GmbHHolding Indirect Cologne DE; holding indirect 100%
Lonza Costa Rica, S.A.Holding Indirect Heredia CR; holding indirect 100%
Lonza Finance International NVHolding Indirect Bornem BE; holding indirect 100%
Lonza Greenwood LLCHolding Indirect Wilmington US; holding indirect 100%
Lonza Guangzhou Pharmaceutical LtdHolding Indirect Guangzhou CN; holding indirect 100%
Lonza Houston Inc.Holding Indirect Wilmington US; holding indirect 100%
Lonza Licences AGHolding Indirect Basel CH; holding indirect 100%
Lonza K.K.Holding Indirect Sagamihara JP; holding indirect 100%
Lonza Manufacturing LLCHolding Indirect Wilmington US; holding indirect 100%
Lonza Netherlands B.V.Holding Indirect Geleen NL; holding indirect 100%
Lonza Rockland, Inc.Holding Indirect Wilmington US; holding indirect 100%
Lonza Sales AGHolding Direct Basel CH; holding direct 100%
Lonza Shanghai International Trading Ltd.Holding Indirect Shanghai CN; holding indirect 100%
Lonza Swiss Finanz AGHolding Indirect Basel CH; holding indirect 100%
Lonza Swiss Licences AGHolding Indirect Basel CH; holding indirect 100%
Lonza Tampa LLCHolding Indirect Wilmington US; holding indirect 100%
Lonza (Thailand) Co., Ltd.Holding Indirect Bangkok TH; holding indirect 100%
Lonza USA Inc.Holding Indirect Wilmington US; holding indirect 100%
Lonza Verviers SRLHolding Indirect Verviers BE; holding indirect 100%
Lonza Walkersville, Inc.Holding Indirect Wilmington US; holding indirect 100%
Micro-Macinazione SAHolding Indirect Monteggio CH; holding indirect 100%
Octane Biotech, Inc.Holding Indirect Ontario CA; holding indirect 80%
P.T. Capsugel IndonesiaHolding Indirect Jakarta IN; holding indirect 100%
Suzhou Capsugel LimitedHolding Indirect Suzhou CN; holding indirect 75%
Synaffix B.V.Holding Indirect Oss NL; holding indirect 100%

Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.

Senior executives

Key management

Key management

ItemValuePeriod / scopeSource
Wolfgang Wienand Chief Executive Officer Executive Committee as of 31 December 2025 · As at 2025-12-31 PDF p. 111
Philippe Deecke Chief Financial Officer Executive Committee as of 31 December 2025 · As at 2025-12-31 PDF p. 111
Maria Soler Nunez Chief Quality Officer Executive Committee as of 31 December 2025 · As at 2025-12-31 PDF p. 111
Nicoleta Baumgärtner Chief Human Resources Officer Executive Committee as of 31 December 2025 · As at 2025-12-31 PDF p. 111
Andreas Bohrer Chief Legal & Corporate Affairs Officer Executive Committee as of 31 December 2025 · As at 2025-12-31 PDF p. 111
Jason Berndt Head of Group Operations Executive Committee as of 31 December 2025 · As at 2025-12-31 PDF p. 111
Gordon Bates Head of Integrated Biologics Executive Committee as of 31 December 2025 · As at 2025-12-31 PDF p. 111
Christian Seufert Head of Advanced Synthesis Executive Committee as of 31 December 2025 · As at 2025-12-31 PDF p. 111
Daniel Palmacci Head of Specialized Modalities Executive Committee as of 31 December 2025 · As at 2025-12-31 PDF p. 111
Jean-Christophe Hyvert Head of Capsules & Health Ingredients Executive Committee as of 31 December 2025 · As at 2025-12-31 PDF p. 111

Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.

Shareholding statistics

Share capital & shareholders

Share capital

ItemValuePeriod / scopeSource
Total number of shares 70,229,021 shares 31.12.2025; comparative 31.12.2024: 72,226,184 · As at 2025-12-31 PDF p. 104
Registered shares with voting rights 24,619,656 shares 31.12.2025; comparative 31.12.2024: 24,431,971 · As at 2025-12-31 PDF p. 104

Treasury shares

ItemValuePeriod / scopeSource
Treasury shares without voting rights 0.55% Shares in %, 31.12.2025; comparative 31.12.2024: 0.12 · As at 2025-12-31 PDF p. 104
Share buyback 0.00% Shares in %, 31.12.2025; comparative 31.12.2024: 2.09 · As at 2025-12-31 PDF p. 104

Shareholding distribution

ItemValuePeriod / scopeSource
Registered shareholders 56,471 shareholders 31.12.2025; comparative 31.12.2024: 53,784 · As at 2025-12-31 PDF p. 104
1–100 45,785 shareholders Number of registered shareholders, 31.12.2025; comparative 31.12.2024: 43,020 · As at 2025-12-31 PDF p. 104
101–1,000 9,421 shareholders Number of registered shareholders, 31.12.2025; comparative 31.12.2024: 9,511 · As at 2025-12-31 PDF p. 104
1,001–10,000 1,027 shareholders Number of registered shareholders, 31.12.2025; comparative 31.12.2024: 1,016 · As at 2025-12-31 PDF p. 104
10,001–100,000 206 shareholders Number of registered shareholders, 31.12.2025; comparative 31.12.2024: 202 · As at 2025-12-31 PDF p. 104
100,001–1,000,000 27 shareholders Number of registered shareholders, 31.12.2025; comparative 31.12.2024: 31 · As at 2025-12-31 PDF p. 104
Over 1,000,000 5 shareholders Number of registered shareholders, 31.12.2025; comparative 31.12.2024: 4 · As at 2025-12-31 PDF p. 104
Shares in transit 57.98% Shares in %, 31.12.2025; comparative 31.12.2024: 59.25 · As at 2025-12-31 PDF p. 104

Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.

Related parties, people & properties

Other disclosures

Employees

ItemValuePeriod / scopeSource
Average number of employees (Full-Time Equivalent) 16,866 FTE Group, continuing business, 2025 (comparative 2024 restated: 15,734) PDF p. 50

Subsequent events

ItemValuePeriod / scopeSource
Share buyback program The Company intends to initiate a share buyback program for CHF 500 million spanning 12 months, following the receipt of the proceeds from Lone Star Funds. Lonza Group Ltd PDF p. 80

Outlook

ItemValuePeriod / scopeSource
The Year Ahead we are well positioned to continue executing our CEO letter PDF p. 5

Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.

Source: Annual Report 2025 ↗

Corporate information

Registration & contacts

Incorporated In
OTHERS
Incorporated On
16 Mar 1999
Telephone
+41 61 316 8111
Fax
+41 61 316 9111
Registered Office
Muenchensteinerstrasse 38
CH-4002 Basel
Switzerland
Secretary
Andreas Bohrer
Registrar / Transfer Agent
SIX SAG AG (SWITZERLAND) \
BOARDROOM CORPORATE & ADVISORY SERVICES PTE. LTD.
Registrar Address
SIX SAG AG P.O. Box CH-4601 Olten, Switzerland/1 Harbourfront Avenue, Keppel Bay Tower, #14-07, Singapore 098632
Auditors
DELOITTE LTD, ZURICH (CH)
Other Stock Exchange Listings
SIX SWISS EXCHANGE
Country
OTHERS
Security Type
stocks